Regulus Therapeutics Inc (RGLS) Receives $1.13 Consensus PT from Brokerages
Regulus Therapeutics Inc (NASDAQ:RGLS) has received a consensus rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $1.13.
Several equities research analysts have recently commented on the company. Wedbush set a $2.00 price target on Regulus Therapeutics and gave the stock a “hold” rating in a research note on Friday, January 25th. Zacks Investment Research cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 6th.
Shares of Regulus Therapeutics stock traded up $0.03 during trading hours on Friday, hitting $0.91. 24,691 shares of the company were exchanged, compared to its average volume of 309,841. Regulus Therapeutics has a 1 year low of $0.80 and a 1 year high of $15.60. The stock has a market capitalization of $7.71 million, a PE ratio of -0.08 and a beta of 2.24.
A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC raised its position in Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the period. Renaissance Technologies LLC owned about 6.82% of Regulus Therapeutics worth $118,000 at the end of the most recent reporting period.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Recommended Story: Bull Market
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.